The project, launched in November 2019, was carried out throughout 2020, sometimes slowing the development, but steadily progressing, and will yield outstanding results that we are looking forward to sharing with you toward the end of February. The study was carefully devised and produced detailed results based on sound data collected from all stakeholders. We read more…
Category Archives: About IQN Path
SeraCare to Develop NGS Standards for Tumor Mutational Burden Monitoring
This article was originally published on http://www.clpmag.com/2019/04/seracare-develop-ngs-standards-tumor-mutational-burden-monitoring/ Under its agreement with IQN Path, SeraCare will develop, manufacture, and supply a range of highly characterized cell line genomic DNA and formalin-fixed, paraffin-embedded standards with confirmed low, mid, and high levels of mutational burden within their exome regions. Beginning in June 2019, the materials will be sent read more…
IQN Path Selects SeraCare Life Sciences for First-Ever Tumor Mutational Burden External Quality Assessment Program
International expert group focused on improving quality of clinical biomarker testing launching pilot TMB proficiency program in Spring 2019 MILFORD, Mass., WED. March 27, 2019 /PRNewswire/ — SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, announced today their successful selection as a technology partner read more…
IQN Path Members Area
One of the benefits of being a member of IQN Path is that all member organisations have access to our secure member’s area on the IQN Path website. In this area we post all manner of papers including Governance documents and the Annual IQN Path report. Meeting summaries and agendas, both general meetings but also read more…